JP2019524834A5 - - Google Patents

Download PDF

Info

Publication number
JP2019524834A5
JP2019524834A5 JP2019508879A JP2019508879A JP2019524834A5 JP 2019524834 A5 JP2019524834 A5 JP 2019524834A5 JP 2019508879 A JP2019508879 A JP 2019508879A JP 2019508879 A JP2019508879 A JP 2019508879A JP 2019524834 A5 JP2019524834 A5 JP 2019524834A5
Authority
JP
Japan
Prior art keywords
therapeutic agent
epilepsy
agent according
patient
syndrome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019508879A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019524834A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/047505 external-priority patent/WO2018035408A1/en
Publication of JP2019524834A publication Critical patent/JP2019524834A/ja
Publication of JP2019524834A5 publication Critical patent/JP2019524834A5/ja
Pending legal-status Critical Current

Links

JP2019508879A 2016-08-18 2017-08-18 ビグアナイド系による発達障害の治療方法 Pending JP2019524834A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662376488P 2016-08-18 2016-08-18
US62/376,488 2016-08-18
PCT/US2017/047505 WO2018035408A1 (en) 2016-08-18 2017-08-18 Methods of treating developmental disorders with biguanides

Publications (2)

Publication Number Publication Date
JP2019524834A JP2019524834A (ja) 2019-09-05
JP2019524834A5 true JP2019524834A5 (cg-RX-API-DMAC7.html) 2020-09-24

Family

ID=61190982

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019508879A Pending JP2019524834A (ja) 2016-08-18 2017-08-18 ビグアナイド系による発達障害の治療方法

Country Status (9)

Country Link
US (2) US10123979B2 (cg-RX-API-DMAC7.html)
EP (1) EP3484452A4 (cg-RX-API-DMAC7.html)
JP (1) JP2019524834A (cg-RX-API-DMAC7.html)
KR (1) KR20190039974A (cg-RX-API-DMAC7.html)
CN (1) CN109715144A (cg-RX-API-DMAC7.html)
AU (1) AU2017313823A1 (cg-RX-API-DMAC7.html)
CA (1) CA3033967A1 (cg-RX-API-DMAC7.html)
MX (1) MX2019001937A (cg-RX-API-DMAC7.html)
WO (1) WO2018035408A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10295547B2 (en) 2013-03-14 2019-05-21 University Of Florida Research Foundation, Incorporated Use and treatment of di-amino acid repeat-containing proteins associated with ALS
US10509045B2 (en) 2015-05-29 2019-12-17 University Of Florida Research Foundation, Incorporated Methods for diagnosing Huntington's disease
US10940161B2 (en) 2016-04-04 2021-03-09 University Of Florida Research Foundation, Incorporated Manipulation of EIF3 to modulate repeat associated non-ATG (RAN) translation
WO2018035408A1 (en) 2016-08-18 2018-02-22 Ovid Therapeutics Inc. Methods of treating developmental disorders with biguanides
EP3612190A4 (en) * 2017-04-17 2021-01-20 University of Florida Research Foundation, Incorporated REGULATION OF RAN TRANSLATION THROUGH PKR AND EIF2A-P WAYS
EP3688020A4 (en) 2017-09-25 2021-07-14 University of Florida Research Foundation, Incorporated IMMUNOASSAYS FOR DETECTION OF RAN PROTEINS
AU2018342105B2 (en) * 2017-09-26 2023-11-16 University Of Florida Research Foundation, Incorporated Use of metformin and analogs thereof to reduce ran protein levels in the treatment of neurological disorders
GB201912760D0 (en) * 2019-09-05 2019-10-23 Healx Ltd Treatment
AU2020348916B2 (en) 2019-09-20 2025-12-18 University Of Florida Research Foundation, Incorporated Detection of antibodies against RAN proteins from serum and tissue lysates
WO2021072187A2 (en) 2019-10-10 2021-04-15 University Of Florida Research Foundation, Incorporated Ran proteins as biomarkers in cag/ctg expansion disorders
GB202008699D0 (en) * 2020-06-09 2020-07-22 Healx Ltd Treatment
CN113318111B (zh) * 2021-06-21 2026-02-03 浙江大学 Nav1.1激动剂在制备治疗自闭症的药物中的应用
US20250041247A1 (en) * 2021-12-01 2025-02-06 University Of Florida Research Foundation, Incorporated Small molecule inhibitors of repeat associated non-aug (ran) translation and combination therapies
US20230186023A1 (en) * 2021-12-13 2023-06-15 International Business Machines Corporation Automatically assign term to text documents

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6099859A (en) * 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
AU2003261298A1 (en) * 2002-08-02 2004-02-23 Penwest Pharmaceuticals Company Sustained release formulations of metformin
US20060147947A1 (en) * 2002-12-04 2006-07-06 Javier Apfeld AMPK pathway components
US8252321B2 (en) * 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
WO2008097861A2 (en) * 2007-02-02 2008-08-14 Braincells, Inc. MODULATION OF NEUROGENESIS WITH BIGUANIDES AND GSK3-ß AGENTS
CN102058888B (zh) * 2009-05-01 2014-06-11 常州高新技术产业开发区三维工业技术研究所有限公司 一种治疗能量代谢异常的药物组合物和其应用
EP2653158B1 (en) * 2010-12-13 2017-07-05 Fukuoka University Therapeutic agent for blood-brain barrier disruption syndrome
EP3013371A4 (en) * 2013-06-26 2017-04-26 Rett Syndrome Research Trust Rett syndrome and treatments therefore
WO2018035408A1 (en) 2016-08-18 2018-02-22 Ovid Therapeutics Inc. Methods of treating developmental disorders with biguanides

Similar Documents

Publication Publication Date Title
US10912754B2 (en) Methods and compositions for treating excessive sleepiness
AU2018201060B2 (en) 7,8-dihydoxyflavone and 7,8-substituted flavone derivatives, compositions, and methods related thereto
US9718766B2 (en) High penetration drugs and their compositions thereof for treatment of parkinson diseases
JP2024075655A5 (ja) 鏡像異性体的に純粋なブプロピオンの医薬の製造における使用
ES2988617T3 (es) Norketotifeno para el tratamiento de la hipercitocinemia y las infecciones virales
US20200179336A1 (en) Methods of treating neurological and psychiatric disorders
JP2004519469A5 (cg-RX-API-DMAC7.html)
JP2010518122A5 (cg-RX-API-DMAC7.html)
RU2011134499A (ru) Композиция 4-амино-2-(2,6-диоксопиперидин-3-ил)изоиндолин-1,3-диона
JP2011510014A5 (cg-RX-API-DMAC7.html)
JP2023550149A5 (cg-RX-API-DMAC7.html)
JP2011225596A5 (cg-RX-API-DMAC7.html)
UA107578C2 (uk) Комбінована терапія при лікуванні діабету
BRPI0605026A (pt) composição farmacêutica estável de glimepirida com liberação imediata e metformina com liberação prolongada
JP2021152060A (ja) アカンプロセートおよびd−サイクロセリンを使用する組み合わせ療法
JP2022545156A5 (cg-RX-API-DMAC7.html)
JP2014508758A5 (cg-RX-API-DMAC7.html)
RU2013137645A (ru) Аналоги цистамина, применяемые для лечения болезни паркинсона
JP2021527053A5 (cg-RX-API-DMAC7.html)
JP2018531273A5 (cg-RX-API-DMAC7.html)
ES2905771T3 (es) Composiciones y procedimientos para el tratamiento de la inflamación y del dolor
RU2005133665A (ru) Применение производных 10-гидрокси-10,11-дигидрокарбамазепина для лечения аффективных расстройств
ES2315569T3 (es) Procedimiento de tratamiento de trastornos del movimiento usando derivados de acido barbiturico.
TW201828932A (zh) 1,1-二甲基雙胍之亞硝酸鹽、醫藥組合物及使用方法
US11850220B2 (en) Synthesis of ibuprofen hybrid conjugates as anti-inflammatory and analgesic agents